Literature DB >> 21487811

MKK4 acts as a potential tumor suppressor in ovarian cancer.

Shamima Yeasmin1, Kentaro Nakayama, Mohammed Tanjimur Rahman, Munmun Rahman, Masako Ishikawa, Atsuko Katagiri, Kouji Iida, Naomi Nakayama, Kohji Miyazaki.   

Abstract

Our previous studies indicate that loss of MKK4 expression is associated with the progression of ovarian cancer. However, direct evidence that MKK4 inhibits the malignant phenotype of ovarian cancer cells is limited. In the current study, we investigated the mechanism relating loss of MKK4 expression to the development of ovarian cancer. Using cell growth and anchorage-independent assays, we determined that both the growth and colony-forming ability of MKK4-transfected TOV-21G cells, a line with a homozygous deletion of MKK4, were significantly reduced compared to control vector-transfected cells. Overexpression of the MKK4 gene in TOV-21G cells resulted in reduced proliferative activity and increased apoptosis. To confirm that MKK4 expression related to tumor suppress function, we used two independent but complementary approaches. MKK4 gene knockdown in OVK18#2 and MDAH2774 cells, which overexpressed MKK4, increased proliferation activity. Additionally, the engineered expression of MKK4 in SKOV3 cells, a line with low endogenous MKK4 expression, produced a phenotype similar to that of TOV-21G. Similar results were produced in tumor xenografts in nude mice. These results indicated that MKK4 acts as a tumor suppressor and may represent an important therapeutic target for the treatment of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487811     DOI: 10.1007/s13277-011-0166-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  25 in total

Review 1.  Mammalian MAP kinase signalling cascades.

Authors:  L Chang; M Karin
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

Review 2.  Unlocking the potential of the human genome with RNA interference.

Authors:  Gregory J Hannon; John J Rossi
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

3.  Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.

Authors:  Kentaro Nakayama; Naomi Nakayama; Robert J Kurman; Leslie Cope; Gudrun Pohl; Yardena Samuels; Victor E Velculescu; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Biol Ther       Date:  2006-07-26       Impact factor: 4.742

4.  Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.

Authors:  H L Kim; D J Vander Griend; X Yang; D A Benson; Z Dubauskas; B A Yoshida; M A Chekmareva; Y Ichikawa; M H Sokoloff; P Zhan; T Karrison; A Lin; W M Stadler; T Ichikawa; M A Rubin; C W Rinker-Schaeffer
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

5.  MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course.

Authors:  Wei Xin; Ki J Yun; Francesca Ricci; Marianna Zahurak; Wanglong Qiu; Gloria H Su; Charles J Yeo; Ralph H Hruban; Scott E Kern; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

6.  Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines.

Authors:  K Nakayama; K Miyazaki; A Kanzaki; M Fukumoto; Y Takebayashi
Journal:  Oncol Rep       Date:  2001 Nov-Dec       Impact factor: 3.906

7.  Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis.

Authors:  Chuang Huang; Kun Huang; Chi Wang; Zhen-Dong Jiang; Xing-Xing Li; Hong-Peng Wang; Hong-Yan Chen
Journal:  Oncol Rep       Date:  2009-07       Impact factor: 3.906

Review 8.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

9.  The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma.

Authors:  Jonathan A Hickson; Dezheng Huo; Donald J Vander Griend; Anning Lin; Carrie W Rinker-Schaeffer; S Diane Yamada
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

10.  Cancer statistics, 1995.

Authors:  P A Wingo; T Tong; S Bolden
Journal:  CA Cancer J Clin       Date:  1995 Jan-Feb       Impact factor: 508.702

View more
  8 in total

1.  [Expressions of MAP2K4 and estrogen receptor and their clinical significance in invasive breast cancer].

Authors:  Shu Liu; Yi-Yi Liu; Rong Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

2.  Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization.

Authors:  Russell O Bainer; Jennifer Taylor Veneris; S Diane Yamada; Anthony Montag; Mark W Lingen; Yoav Gilad; Carrie W Rinker-Schaeffer
Journal:  Clin Exp Metastasis       Date:  2012-02-21       Impact factor: 5.150

3.  Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers.

Authors:  Vidhu Sharma; Lisa Young; Anne B Allison; Kate Owen
Journal:  Elife       Date:  2016-02-19       Impact factor: 8.140

4.  Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma.

Authors:  Ling-Hao Zhao; Xiao Liu; He-Xin Yan; Wei-Yang Li; Xi Zeng; Yuan Yang; Jie Zhao; Shi-Ping Liu; Xue-Han Zhuang; Chuan Lin; Chen-Jie Qin; Yi Zhao; Ze-Ya Pan; Gang Huang; Hui Liu; Jin Zhang; Ruo-Yu Wang; Yun Yang; Wen Wen; Gui-Shuai Lv; Hui-Lu Zhang; Han Wu; Shuai Huang; Ming-Da Wang; Liang Tang; Hong-Zhi Cao; Ling Wang; Tin-Lap Lee; Hui Jiang; Ye-Xiong Tan; Sheng-Xian Yuan; Guo-Jun Hou; Qi-Fei Tao; Qin-Guo Xu; Xiu-Qing Zhang; Meng-Chao Wu; Xun Xu; Jun Wang; Huan-Ming Yang; Wei-Ping Zhou; Hong-Yang Wang
Journal:  Nat Commun       Date:  2016-10-05       Impact factor: 14.919

5.  Downregulation of phosphorylated MKK4 is associated with a poor prognosis in colorectal cancer patients.

Authors:  Pu-Ning Wang; Jun Huang; Ying-Hua Duan; Jia-Min Zhou; Pin-Zhu Huang; Xin-Juan Fan; Yan Huang; Lei Wang; Huan-Liang Liu; Jian-Ping Wang; Mei-Jin Huang
Journal:  Oncotarget       Date:  2017-05-23

6.  MAP2K4 interacts with Vimentin to activate the PI3K/AKT pathway and promotes breast cancer pathogenesis.

Authors:  Shu Liu; Juan Huang; Yewei Zhang; Yiyi Liu; Shi Zuo; Rong Li
Journal:  Aging (Albany NY)       Date:  2019-11-25       Impact factor: 5.682

7.  Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.

Authors:  Anna A Marusiak; Natalie L Stephenson; Hayeon Baik; Eleanor W Trotter; Yaoyong Li; Karen Blyth; Susan Mason; Phil Chapman; Lorena A Puto; Jon A Read; Claire Brassington; Hannah K Pollard; Chris Phillips; Isabelle Green; Ross Overman; Matthew Collier; Ewelina Testoni; Crispin J Miller; Tony Hunter; Owen J Sansom; John Brognard
Journal:  Cancer Res       Date:  2015-12-04       Impact factor: 12.701

8.  Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.

Authors:  Janet M Pavese; Irene M Ogden; Eric A Voll; Xiaoke Huang; Li Xu; Borko Jovanovic; Raymond C Bergan
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.